Expanded/​Activated Gamma Delta T-cell Infusion

Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

What's the purpose of the trial?

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
38
Last Updated
3 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • EAGD (Expanded/Activated Gamma Delta) T-cells are T-cells that are removed and genetically modified to help them recognize and kill cancer cells in the body.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

EAGD T-cell infusion

Accepting patients

EAGD T-cell infusion (Expansion)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.